Imaging Evaluation of Central Nervous Autoimmune Diseases

Status Not yet recruiting

Clinical Trial Summary

Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common cause of non traumatic disability in young and middle-aged people. Neuromyelitis optica spectrum disease (nmosd) is an independent disease different from Ms. the pathogenesis and the mode of brain and spinal cord injury are different from MS, and the prognosis and optimal treatment are different. It is difficult to distinguish the two diseases in the early stage. Early diagnosis and treatment of the two diseases can greatly improve the quality of life of patients. Therefore, it is an urgent problem to clarify the difference between MS and nmosd injury patterns and to find sensitive imaging markers for early clinical intervention. With the continuous progress of computer aided diagnosis (CAD), it is more and more widely used in medicine, which is expected to help solve the above problems. The purpose of this study is to create a neuroimmune disease evaluation database based on image data. By combining brain and spinal cord imaging, and based on Zhang quantum space learning computer-aided technology, we can achieve accurate segmentation of MS and nmosd brain and spinal cord lesions, analyze the evolution characteristics of the disease at different time points, and screen the imaging indexes related to clinical scores combined with clinical and laboratory indexes Objective: to determine the different prognosis and its influencing factors at the clinical, imaging and molecular levels, and establish the model for predicting disease progression and prognosis, so as to provide the basis for early identification and assistance in guiding treatment and judging prognosis. Clinical information was collected: age, gender, course of disease, MMSE, EDSS disability score, nine hole test, 25 foot walking test. Assess the patient's information processing ability. Blood samples were collected. Imaging examination was performed. The patients were followed up regularly.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04822623
Study type	Observational
Source	Qilu Hospital of Shandong University
Contact	Xaoyu Han
Phone	18560081083
Email	710804284@qq.com
Status	Not yet recruiting
Phase
Start date	May 1, 2021
Completion date	July 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05154734` - Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders	Phase 1/Phase 2
Withdrawn	`NCT03829566` - Autologous Transplant To End NMO Spectrum Disorder	Phase 2/Phase 3
Recruiting	`NCT05403138` - Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders	Phase 2/Phase 3
Completed	`NCT05432713` - A Study of LP-168 in Healthy Volunteers	Phase 1
Completed	`NCT04227470` - A Study of HBM9161 in NMOSD Patients	Phase 1
Not yet recruiting	`NCT06280755` - Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Recruiting	`NCT05414890` - Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
Recruiting	`NCT05840055` - ACT With NMOSD Patients and Caregivers Pilot Study	N/A
Recruiting	`NCT05004493` - Biorepository and Registry for Plasma Exchange Patients
Completed	`NCT05896605` - Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder	Phase 4
Recruiting	`NCT04106830` - Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)
Completed	`NCT03766347` - Pediatric NMOSD Observational Study
Recruiting	`NCT05154370` - China National Registry of Neuro-Inflammatory Diseases
Recruiting	`NCT06443333` - National, Multicentric Registry Study on Neuroimmunological Diseases in China
Recruiting	`NCT05145361` - Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)	Early Phase 1
Not yet recruiting	`NCT05974293` - A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders	Phase 2
Completed	`NCT04355611` - Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
Recruiting	`NCT05792462` - Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.